Luca Gianni
Impact in
- Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 205
- Cancer Treatment and Pharmacology 99
- HER2/EGFR in Cancer Research 90
-
- Breast Cancer Treatment Studies 54
- Cancer Genomics and Diagnostics 21
- Co-authors
- Giampaolo Bianchini (33 shared papers)Giorgio Minotti (12 shared papers)Emanuela Salvatorelli (7 shared papers)Pierantonio Menna (6 shared papers)Gaetano Cairo (1 shared paper)Melinda E. Sanders (2 shared papers)Ingrid A. Mayer (1 shared paper)Justin M. Balko (1 shared paper)
- Journals
- Journal of Clinical Oncology (75 papers)Annals of Oncology (46 papers)Cancer Research (19 papers)European Journal of Cancer (13 papers)The Lancet Oncology (6 papers)
- Partner nations
- ItalyUnited StatesSpain
In The Last Decade
Luca Gianni
300 papers receiving 30.2k citations
Luca Gianni's Hit Papers
Peers
Comparison fields: 5 of 154
- Oncology 16.4k
- Cancer Research 6.4k
- Radiology, Nuclear Medicine and Imaging 4.2k
- Cardiology and Cardiovascular Medicine 3.1k
- Pulmonary and Respiratory Medicine 4.4k
Countries citing papers authored by Luca Gianni
This map shows the geographic impact of Luca Gianni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Gianni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Gianni more than expected).
Fields of papers citing papers by Luca Gianni
This network shows the impact of papers produced by Luca Gianni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Gianni. The network helps show where Luca Gianni may publish in the future.
Co-authors
The 25 scholars most cited alongside Luca Gianni, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 304 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Hit paper breakdown → | 2004 | 3040 |
| 2 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2012 | 2724 |
| 3 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease Hit paper breakdown → | 2016 | 2122 |
| 4 | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Hit paper breakdown → | 2011 | 1566 |
| 5 | Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Hit paper breakdown → | 2010 | 900 |
| 6 | Treatment landscape of triple-negative breast cancer — expanded options, evolving needs Hit paper breakdown → | 2021 | 870 |
| 7 | HER2-positive breast cancer Hit paper breakdown → | 2016 | 757 |
| 8 | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Hit paper breakdown → | 2017 | 704 |
| 9 | Treatment of HER2-positive breast cancer: current status and future perspectives Hit paper breakdown → | 2011 | 700 |
| 10 | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types Hit paper breakdown → | 2002 | 683 |
| 11 | Triple-negative breast cancer: disease entity or title of convenience? Hit paper breakdown → | 2010 | 657 |
| 12 | Triple-Negative Breast Cancer: An Unmet Medical Need Hit paper breakdown → | 2011 | 635 |
| 13 | 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial Hit paper breakdown → | 2016 | 568 |
| 14 | European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Hit paper breakdown → | 1994 | 516 |
| 15 | Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2017 | 477 |
| 16 | 1995 | 460 | |
| 17 | 2005 | 458 | |
| 18 | 2010 | 455 | |
| 19 | 1995 | 450 | |
| 20 | 2008 | 369 |
About Luca Gianni
Luca Gianni is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 304 papers that have together received 30.9k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (99 papers), HER2/EGFR in Cancer Research (90 papers), Breast Cancer Treatment Studies (54 papers), Advanced Breast Cancer Therapies (39 papers), Monoclonal and Polyclonal Antibodies Research (23 papers), Chemotherapy-induced cardiotoxicity and mitigation (22 papers), Cancer Genomics and Diagnostics (21 papers) and Lung Cancer Treatments and Mutations (19 papers). The work is most often cited by research in Oncology (16.4k citations), Cancer Research (6.4k citations), Radiology, Nuclear Medicine and Imaging (4.2k citations), Cardiology and Cardiovascular Medicine (3.1k citations) and Pulmonary and Respiratory Medicine (4.4k citations). Luca Gianni has collaborated with scholars based in Italy, United States and Spain. Frequent co-authors include Giampaolo Bianchini, Giorgio Minotti, Emanuela Salvatorelli, Pierantonio Menna, Gaetano Cairo, Melinda E. Sanders, Ingrid A. Mayer, Justin M. Balko, José Baselga and Sibylle Loibl. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, European Journal of Cancer and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.